Large-cap Health Care company Teva Pharmaceutical Industries has logged a 2.4% change today on a trading volume of 937,409. The average volume for the stock is 6,812,023.
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. Based in Tel Aviv, Israel the company has 37,000 full time employees and a market cap of $19,441,014,784.
The company is now trading -23.79% away from its average analyst target price of $22.36 per share. The 9 analysts following the stock have set target prices ranging from $18.0 to $26.0, and on average give Teva Pharmaceutical Industries a rating of buy.
Over the last 52 weeks, TEVA stock has risen 65.5%, which amounts to a 33.1% difference compared to the S&P 500. The stock's 52 week high is $19.31 whereas its 52 week low is $9.35 per share. Based on Teva Pharmaceutical Industries's average net margin growth of 22.3% over the last 6 years, its core business is on track for profitability and its strong stock performance may continue in the long term.
| Date Reported | Total Revenue ($ k) | Net Profit ($ k) | Net Margins (%) | YoY Growth (%) |
|---|---|---|---|---|
| 2023 | 15,846,000 | -559,000 | -4 | 75.0 |
| 2022 | 14,925,000 | -2,446,000 | -16 | -633.33 |
| 2021 | 15,878,000 | 417,000 | 3 | 112.5 |
| 2020 | 16,659,000 | -3,990,000 | -24 | -300.0 |
| 2019 | 16,887,000 | -999,000 | -6 | 62.5 |
| 2018 | 18,271,000 | -2,886,000 | -16 |
